Colorectal Cancer

Colorectal Cancer Alliance urges action through Project Cure CRC.

Dr. Nicholas Hornstein explained the concept of ctDNA and how this blood test may help guide treatment decisions, including whether additional therapy is needed.

In BREAKWATER, EC plus FOLFIRI achieved a 64.4% response rate and showed a trend toward improved overall survival in patients with BRAF V600E mCRC.

Study findings show more colorectal cancer risk reduction and safety with the use of a GLP-1RA versus Aspirin.

Physical activity, especially walking, was linked to less fatigue and better quality of life for patients with colorectal cancer, particularly in early survivorship.

Dr. Thejus Jayakrishnan discussed how patients and physicians weigh treatment options in later-line metastatic colorectal cancer.

Patients with stage 3 colorectal cancer who tested MRD-positive with Signatera after surgery saw a meaningful survival benefit from Celebrex plus chemotherapy.

The FDA granted fast track status to muzastotug plus Keytruda for adults with microsatellite stable metastatic colorectal cancer without liver metastases.

Dr. Joshua Sabari sat down with Dr. Michael Cecchini to discuss advances in colorectal cancer management and key data presented at the 2025 ESMO Congress.

$100 Million Initiative by Colorectal Cancer Alliance Aims to Accelerate Progress.

After a surprise diagnosis at 47, salon owner Christa Messmer found strength, faith and renewed meaning in life while facing colorectal cancer.

The FDA grants fast track status to alnodesertib plus low-dose irinotecan for third-line metastatic colorectal cancer with ATM deficiency.

Colorectal cancer is a complex disease. Understanding its fundamental aspects can empower you to have more informed and productive conversations with your oncologist.

Rising colorectal cancer rates in younger adults are prompting earlier screenings, with colonoscopy offering both detection and prevention.

FDA grants D3S-001 treatment breakthrough therapy for KRAS G12C some with lung cancer and orphan drug status for KRAS G12C colorectal cancer in adults.

The FDA granted breakthrough device designation to Quest Diagnostics’ Haystack MRD test for patients with stage 2 colorectal cancer after surgery.

The FDA approved the Dako Omnis panel to identify patients with colorectal cancer with mismatch repair deficiency.

Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.

The FDA approved an investigational new drug application for ABT-301, clearing the way for a new clinical trial in metastatic colorectal cancer to begin.

Writing helped me focus on gratitude and healing after my colon cancer diagnosis, transforming the act into a powerful recovery tool.

Three of five patients with advanced colorectal cancer responded to leronlimab, including one complete response lasting five years, according to new data.

The Colorectal Cancer Alliance initiative is bridging gaps in cancer care progress with grants totaling almost $12 Million.

Zanzalintinib plus Tecentriq significantly improved overall survival versus Stivarga in previously treated metastatic colorectal cancer, phase 3 data show.

Tecentriq and chemotherapy combination reduces the risk of death versus chemotherapy alone in deficient mismatch repair, stage 3 colorectal cancer.

Alliance survey reveals most Americans deprioritize colorectal cancer screening, yet screening & innovative research are critical to survivorship.